Author:
Aoe Michinori,Shimada Akira,Muraoka Michiko,Washio Kana,Nakamura Yoshimi,Takahashi Takahide,Imada Masahide,Watanabe Toshiyuki,Okada Ken,Nishiuchi Ritsuo,Miyamura Takako,Chayama Kosuke,Shibakura Misako,Oda Megumi,Morishima Tsuneo
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10:957–63.
2. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998–1006.
3. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27:5175–81.
4. Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, et al. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children’s Oncology Group (COG) study. Br J Haematol. 2012;157:507–10.
5. Tamamyan G, Chao YH, Wang CH, Wu HP, Weng T, Peng CT, Wu KH. Dasatinib plus chemotherapy to achieve full donor chimerism and complete molecular remission in a child with relapsed philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:1727–8.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献